RHHBY catalysts
Catalysts and events linked to RHHBY, newest first.
RHHBY stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026 2026-10-19 · Up | pipeline net present value accretion from superior Phase III KRAS G12C data | Roche presented Phase III data showing divarasib superiority over existing KRAS G12C inhibitors. | Not recorded |
| Roche sets up pivotal ESMO data across lung and breast cancer 2026-10-19 · Up | late-stage oncology data can support pipeline valuation and earnings durability | The source says Roche will present pivotal Phase III data at ESMO 2026 across lung and breast cancer. | Not recorded |
| ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian Candidate 2026-10-19 · Up | Phase 3 clinical superiority confirmation across late-stage oncology assets | Source shows Phase III divarasib superiority over first-generation KRAS G12C inhibitors. | Not recorded |
| Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMO 2026-10-19 · Up | expanded addressable market in lung and breast cancer indications | Phase III data showed divarasib superiority over first-generation KRAS G12C inhibitors and improved efficacy for giredestrant. | Not recorded |
| Roche to present pivotal Phase III oncology data at ESMO 2026 2026-10-19 · Up | pipeline de-risking and terminal value upgrades on oncology franchise | Roche announced pivotal Phase III data demonstrating divarasib superiority and giredestrant efficacy at ESMO 2026. | Not recorded |
| Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide 2026-09-23 · Up | pipeline net present value expansion in metabolic therapeutic franchise | Roche announced Phase II data with 15.5% weight loss and 2.65% HbA1c reduction. | Not recorded |
| Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide 2026-09-23 · Up | expansion of late-stage metabolic pipeline commercial valuation | Roche reported 15.5% body weight loss and 2.65% HbA1c drop at 24 mg dose in Phase II study. | Not recorded |
| Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways 2026-09-17 · Watch | cardiovascular therapeutic pipeline expansion and clinical readouts | Roche listed among key biopharma developers pursuing novel hypertension mechanisms. | Not recorded |
Do these developments change your position?
Review RHHBY alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
See today's live cards
6 live catalysts on RHHBY are in Desk now. Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.
DateCardAvg 5d
- 2026-10-19Roche to present pivotal Phase III oncology data at ESMO 2026RHHBY
- 2026-10-19Roche sets up pivotal ESMO data across lung and breast cancerRHHBY
- 2026-10-19Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026RHHBY ZNTL
- 2026-10-19ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian CandidateRHHBY ZNTL
- 2026-10-19Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMORHHBY
- 2026-10-19Roche to present pivotal Phase III oncology data at ESMO 2026RHHBY
- 2026-10-19ESMO Congress Abstracts Reveal 15.8-Month Overall Survival for Zentalis Ovarian CandidateRHHBY ZNTL
- 2026-10-19Roche sets up pivotal ESMO data across lung and breast cancerRHHBY
- 2026-10-19Roche and Zentalis Present Pivotal Oncology Survival and Efficacy Data at ESMO 2026RHHBY ZNTL
- 2026-10-19Roche Presents Pivotal Phase III Data for Divarasib and Giredestrant at ESMORHHBY
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideRHHBY
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideRHHBY
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideLLY NVO RHHBY-0.68%
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist EnicepatideLLY NVO RHHBY-0.68%
- 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysGSK RHHBY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.